Role of lipoxygenases and lipoxin A(4)/annexin-1 receptor in gastric protection induced by 20% ethanol or sodium salicylate in rats.
The role of cyclooxygenases and prostaglandins in experimental models of gastroprotection is well established. We investigated the effects of the 5-lipoxygenase inhibitor A63162, the 12-lipoxygenase inhibitor baicalein and the 15-lipoxygenase inhibitor PD146176 as well as the nonspecific lipoxin A(4)/annexin-1 antagonist Boc1 on adaptive protection induced by 20% ethanol against 70% ethanol, and on protection induced by sodium salicylate against the mucosal-damage-aggravating effects of celecoxib and dexamethasone during local ischemia-reperfusion in rats. It was found that both types of gastroprotection were antagonized by the lipoxygenase inhibitors and the lipoxin A(4)/annexin-1 antagonist in doses that have no direct damaging effect on gastric mucosa. The results suggest that not only cyclooxygenases, but also active lipoxygenases and, possibly, annexin-1 are required for these types of gastroprotection to occur.
Peskar
Brigitta M
BM
Department of Experimental Clinical Medicine, Ruhr University of Bochum, Bochum, Germany. brigitta.m.peskar@rub.de
Ehrlich
Karlheinz
K
Schuligoi
Rufina
R
Peskar
Bernhard A
BA
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D017302:Annexins / Q000378:metabolism*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology; D004347:Drug Interactions; D000431:Ethanol / Q000494:pharmacology*; D044950:Flavanones / Q000494:pharmacology; D005449:Fluorenes / Q000494:pharmacology; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D005938:Glucocorticoids / Q000494:pharmacology; D008084:Lipoxygenase / Q000502:physiology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010647:Phenyl Ethers; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044042:Receptors, Formyl Peptide / Q000502:physiology*; D044067:Receptors, Lipoxin / Q000037:antagonists & inhibitors*; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D012980:Sodium Salicylate / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology
C106248:6,11-dihydro-5-thia-11-aza-benzo(a)-fluorene; D000081:Acetamides; D017302:Annexins; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D044950:Flavanones; D005449:Fluorenes; D005938:Glucocorticoids; D016859:Lipoxygenase Inhibitors; D009842:Oligopeptides; D010647:Phenyl Ethers; D011448:Prostaglandin Antagonists; D011720:Pyrazoles; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; D013449:Sulfonamides; C482540:lipoxin A(4) receptor, rat; C068663:N-hydroxy-N-(1-(4-(phenylmethoxy)phenyl)ethyl)-acetamide; D000431:Ethanol; C006680:baicalein; C046832:t-butyloxycarbonyl-methionyl-leucyl-phenylalanine; D003907:Dexamethasone; D008084:Lipoxygenase; D000068579:Celecoxib; D012980:Sodium Salicylate